Cytokinetics reports Q1 EPS ($1.36), consensus ($1.36)

Reports Q1 revenue $1.58M, consensus $2.61M. “In the first quarter, we made progress towards commercial readiness and advanced our specialty cardiology pipeline,” said Robert Blum, Cytokinetics (CYTK)’ President and Chief Executive Officer. “Recently, our PDUFA date for aficamten in obstructive HCM was extended by FDA to provide time to review a REMS submission made at the Agency’s request subsequent to the initial NDA filing acceptance. We remain confident in the distinct benefit-risk and pharmaceutic profile of aficamten, and our top priority is bringing this potential therapy to patients. This month, we also expect to report topline results from MAPLE-HCM, and we continue conduct of ACACIA-HCM, for which we have now completed enrollment of patients. With a strong balance sheet and prudent attention to capital deployment, we are well positioned to deliver across regulatory, clinical and commercial milestones.”